Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Patient characteristics and results of survival analysis for primary glioblastoma patients when stratified by MGMT methylation status

From: MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Overall survival   MGMT methylation status
  Total qMSP Pyrosequencing
   Methylated Unmethylated Methylated Unmethylated
Patients (n) 58 19 39 29 29
Male/Female 31/27 10/9 21/18 15/14 16/13
Mean agea
(Standard deviation)
58.5
(9.1)
57.5
(8.7)
59.0
(9.3)
59.3
(8.5)
57.7
(9.7)
Median survivalb
(Standard error)
13.1
(1.1)
17.6
(4.2)
12.2
(1.0)
16.1
(3.7)
11.5
(0.4)
2-years overall survival (%)
(Standard error)
21.8
(0.06)
35.5
(0.11)
15.4
(0.06)
33.6
(0.09)
10.3
(0.06)
  1. a)Years; b) Months